Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • Searching Asian documents: patent search and monitoring services
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet and OPS
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Patent insight reports
    • Data
      • Overview
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge

    UP search

    Learn about the Unitary Patent in patent knowledge products and services

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Find a professional representative
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Unitary Patent

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • EPC Guidelines
      • PCT-EPO Guidelines
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National law relating to the UP
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives

    legal text

    Legal texts

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Firefighting technologies
      • Green tech in focus
      • CodeFest on Green Plastics
      • Clean energy technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    Listen to our podcast

  • Learning

    Learning

    The e-Academy – the point of access to your learning

    Go to overview 

    • Overview
    • European Patent Academy
      • Overview
      • Learning activities
      • Learning paths
    • Professional hub
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by area by profile
      • Overview
      • Business and IP managers
      • EQE candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)

    European Patent Academy

    Boost your IP knowledge with (e-)training from the European Patent Academy

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • A glimpse of the planned activities
      • Kids’ collaborative art competition
      • 50 Leading Tech Voices
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Governance
      • Overview
      • Communiqués
      • Calendar
      • Select Committee documents
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Public consultation on the EPO's Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Social responsibility
      • Overview
      • Environment and sustainability
      • Art collection
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s

    about us

    Patent Index 2022

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • Searching Asian documents
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
            • Go back
            • Overview
            • BG - Federated Register Service
            • GB - Federated Register Service
            • NL - Federated Register Service
            • MK - Federated Register Service
            • ES - Federated Register Service
            • GR - Federated Register Service
            • SK - Federated Register Service
            • FR - Federated Register Service
            • MT - Federated Register Service
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Patent insight reports
    • Data
      • Go back
      • Overview
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
          • Go back
          • EBD files (weekly download) - free of charge
            • Go back
            • Secure EBD ST.36 files (weekly download) - for national patent offices only
        • Boards of Appeal decisions
        • EP full-text data for text analytics
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Helpful resources
      • Go back
      • Overview
      • First time here? Patent information explained.
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Unitary Patent Guide
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Online Filing 2.0 pilot
        • MyEPO Portfolio - pilot phase
        • Online Filing 2.0 pilot continuation
        • Exchange data with us using an API
      • Get access
        • Go back
        • Overview
        • Installation and activation
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • EPC Guidelines
        • Go back
        • Overview
        • Archive
      • PCT-EPO Guidelines
        • Go back
        • Overview
        • Archive
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2023 ceremony
      • European Inventor Network
        • Go back
        • Activities granted in 2023
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • CodeFest on Green Plastics
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Patents and standards
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • European Patent Academy
      • Go back
      • Overview
      • Learning activities
      • Learning Paths
    • Professional hub
      • Go back
      • Overview
      • EPAC - European patent administration certification
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Archive
        • Candidates successful in the European qualifying examination
        • Compendium
          • Go back
          • Overview
          • Pre-examination
          • Paper A
          • Paper B
          • Paper C
          • Paper D
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
        • Go back
        • Overview
        • Patent enforcement in Europe
        • Patent litigation in Europe
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventors' handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
            • Go back
            • Overview
            • Is the idea ‘obvious’?
            • Prior art searching
            • Professional patent searching
            • Simple Espacenet searching
            • What is prior art?
            • Why is novelty important?
          • Competition and market potential
            • Go back
            • Overview
            • Research guidelines
          • Assessing the risk ahead
            • Go back
            • Overview
            • Exploitation routes
            • Significant commercial potential
            • Significant novelty
            • What about you?
            • What if your idea is not novel but does have commercial potential?
          • Proving the invention
            • Go back
            • Overview
            • Help with design or redesign
            • Prototype strategy
          • Protecting your idea
            • Go back
            • Overview
            • Forms of IPR
            • Patenting strategy
            • The patenting process
          • Building a team and seeking funding
            • Go back
            • Overview
            • Building a team
            • Sources of funding
            • Sources of help for invention
          • Business planning
            • Go back
            • Overview
            • Constructing a business plan
            • Keep it short!
          • Finding and approaching companies
            • Go back
            • Overview
            • First contact
            • Meetings
          • Dealing with companies
            • Go back
            • Overview
            • Advance or guaranteed payment
            • Companies and your prototype
            • Full agreement – and beyond
            • Negotiating a licensing agreement
            • Reaching agreement
            • Royalties
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • For IP professionals
          • For business decision-makers
          • For stakeholders of the innovation ecosystem
        • IP clinics
      • EQE Candidates
        • Go back
        • Overview
        • Coffee-break questions
        • Daily D questions
        • European qualifying examination - Guide for preparation
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Overview
      • 50 Leading Tech Voices
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Governance
      • Go back
      • Overview
      • Communiqués
        • Go back
        • Overview
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • Invoicing
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • Social responsibility
      • Go back
      • Overview
      • Environment
      • Art collection
        • Go back
        • Overview
        • The collection
        • Let's talk about art
        • Artists
        • Media library
        • What's on
        • Publications
        • Contact
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Procedure
    • Annual reports
      • Go back
      • Overview
    • Organisation
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
        • Composition of the Presidium
          • Go back
          • Overview
          • Archive
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2023
      • Archive
    • Annual list of cases
    • Communications
    • Publications
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
    • Case Law from the Contracting States to the EPC
    • Oral proceedings
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Legal resources
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
      • Specific contact
      • Surveys
        • Go back
        • Overview
        • Search services
        • Examination services, final actions and publication
        • Opposition services
        • Patent filings
          • Go back
          • Overview
          • Detailed methodology
          • Archive
        • Online Services
        • Patent information
          • Go back
          • Overview
          • Innovation process survey
        • Customer services
        • Filing services
        • Website
        • Survey on electronic invoicing
        • Companies innovating in clean and sustainable technologies
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Forums
    • Glossary
Board of Appeals
Decisions

Recent decisions

Overview
  • 2023 decisions
  • 2022 decisions
  • 2021 decisions
https://www.epo.org/en/node/t100050eu1
  1. Home
  2. T 0050/10 (BCRP/University of Maryland) 01-02-2016
Facebook Twitter Linkedin Email

T 0050/10 (BCRP/University of Maryland) 01-02-2016

European Case Law Identifier
ECLI:EP:BA:2016:T005010.20160201
Date of decision
01 February 2016
Case number
T 0050/10
Petition for review of
-
Application number
99908097.1
IPC class
C07K 14/00
C07K 16/00
C07H 21/04
A61K 48/00
A61K 39/395
G01N 33/53
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 406.16 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Breast Cancer Resistance Protein (BCRP) and the DNA which encodes it

Applicant name
University of Maryland Baltimore
Opponent name
Bayer Pharma Aktiengesellschaft
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 54
European Patent Convention Art 56
European Patent Convention Art 83
European Patent Convention Art 87
European Patent Convention R 43(4)
Rules of procedure of the Boards of Appeal Art 12(1)
Rules of procedure of the Boards of Appeal Art 12(4)
Keywords

Priority - main request (yes)

Novelty - main request (yes)

Inventive step - main request (yes)

Sufficiency of disclosure - main request (yes)

Catchword
-
Cited decisions
G 0002/98
R 0010/09
R 0011/11
R 0013/11
Citing decisions
-

I. The appeal was filed by the opponent (appellant) against the interlocutory decision of the opposition division maintaining European patent No. 1 054 894, entitled "Breast Cancer Resistance Protein (BCRP) and the DNA which encodes it" in amended form. The corresponding patent application was filed on 5 February 1999 claiming priority from US application 60/073 763 filed on 5 February 1998.

II. The patent had been opposed under Article 100(a) EPC, on the grounds of lack of novelty (Article 54 EPC), lack of inventive step (Article 56 EPC) and as relating to non-patentable subject-matter (Article 52 EPC in combination with Rule 29(1) EPC) and Articles 100(b) and 100(c) EPC.

III. The opposition division decided that claim 17 of the patent as granted had been amended so as to contain subject-matter extending beyond the content of the application as filed (Article 123(2) EPC). With regard to the claims of auxiliary request 1, which differed from those as granted only in the deletion of claim 17, the opposition division decided that its claims 1 to 8 and 10 to 16 enjoyed the priority date from the US application 60/073 763 and that therefore no objections under Article 54 EPC applied "since the only document cited in this respect (D3) no longer constitute[d] prior art under Article 54(2) EPC." It also found that claims 1 to 3 of auxiliary request 1 met the requirements of Article 52 EPC, that claim 12 met the requirements of Article 83 and that all claims met the requirements of Articles 56 EPC.

IV. With the statement of grounds of appeal, the appellant filed document D19.

V. With the reply the patent proprietor (respondent) inter alia filed its previous auxiliary request 1 as its main request and objected to the admission of document D19 into the proceedings.

VI. Both parties requested oral proceedings in the event of a decision unfavourable to them.

VII. Oral proceedings were appointed for 10 November 2015.

VIII. In a communication dated 1 June 2015, the board informed the parties of its preliminary and non-binding opinion on some of the substantive and legal issues concerning the appeal. In particular, it informed the parties that it considered that the subject-matter of claim 1 of the main request validly claimed the right of priority from US application 60/073 763 and that therefore documents D3, D4 and D5 did not constitute prior art for this subject-matter. Furthermore, the board indicated that it was inclined to agree with the opposition division's finding that the subject-matter of the claims met the requirements of Article 56 EPC and that the subject-matter of claim 12 met the requirements of Article 83 EPC. Finally, the board noted that the admission of the newly filed document D19 would be decided at the oral proceedings, after hearing the parties.

IX. With a submission of 13 August 2015, the appellant withdrew the request for oral proceedings.

X. The board cancelled the oral proceedings scheduled for 10 November 2015 and indicated its intention to issue a decision in writing.

XI. The claims of the main request are as follows:

"1. Polypeptide having the sequence of SEQ ID NO: 1 (Breast Cancer Resistance Protein, BCRP) which induces resistance to cancer chemotherapeutic drugs in breast cancer cells.

2. The polypeptide of claim 1 which is about 655 amino acids in length.

3. The polypeptide of claim 1 which has a molecular mass of 72.3 kilodaltons.

4. An antibody which binds to the polypeptide of claim 1

5. The antibody of claim 4 which is monoclonal.

6. The antibody of claim 4 which is polyclonal.

7. A nucleic acid sequence which encodes the polypeptide of claim 1.

8. The nucleic acid sequence of claim 7 which is the sequence in SEQ ID NO. 2.

9. A nucleic acid comprising the nucleotide sequence of SEQ ID NO: 2.

10. An antisense probe which inhibits expression of the polypeptide of claim 1.

11. The antisense probe of claim 10 which is the complementary strand of the sequence in SEQ ID NO:7.

12. A method of determining the cause of a patient's resistance to cancer chemotherapy drugs by assaying in vitro for expression of the polypeptide of claim 1, whereby overexpression of the said polypeptide indicates that it is the cause.

13. Use of the antibody according to any of claims 4 to 6 for preparing a medicament for inhibiting the activity of the Breast Cancer Resistance Protein.

14. Use of the probe of claim 11 for preparing a medicament for inhibiting the activity of the Breast Cancer Resistance Protein.

15. Use of the antibody of claim 4 for preparing a medicament for enhancing a cancer patient's chemotherapy treatment.

16. Use of the probe of claim 11 for preparing a medicament for enhancing a cancer patient's chemotherapy treatment."

XII. The following documents are cited in this decision.

D1: Allikmets R. et al., Human Molecular Genetics, 5 October 1996, Volume 5, Issue 10, Pages 1649-1655.

D3: Polypeptide sequence Genbank accession no. AAC97367, 21 December 1998.

D4: Allikmets R. et al., Cancer Res., 1 December 1998, Volume 58, Issue 23, Pages 5337-5339.

D5: Miyake K. et al., Cancer Res., 1 January 1999, Volume 59, Issue 1, Pages 8-l3.

D13: Stryer L., Biochemie, 1991, Chapter 35, pages 925-933, Korr. Nachdruck.

D14: Watson D., Rekombinierte DNA, 1993, Chapter 12, pages 209-210, 2. Auflage.

D15: Stryer L., Biochemie, Korr. Nachdruck 1991, last page, Table "Der genetische Standartcode".

D19: Lee et al., Journal of Cellular Biochemistry, 15 June 1997, Volume 65, Issue 4, Pages: 513­-526,

XIII. The appellant's arguments relevant to the decision can be summarised as follows:

Article 12(4) RPBA - Admissibility

Document D19

This document was cited on page 3 of the patent in the "Background of the Invention" and disclosed knowledge on the basis of which the skilled person "would unequivocally arrive at the solution provided in claim 9. Therefore, D19 is introduced in the proceedings".

Articles 54 and 56 EPC - Novelty and Inventive step

Document D1

The subject-matter of claim 2 lacked novelty over the disclosure of document D1 because the term "about" used in the claim meant that the claim was "improperly dependent" on claim 1 and had be to considered as encompassing fragments of SEQ ID NO: 1. Document D1 disclosed such a fragment, EST 157481, designated as an ABC transporter protein which was 100% identical to

SEQ ID NO: 1 over a stretch of 180 amino acids.

Documents D3 to D5

Article 87 EPC - Priority right

SEQ ID NO: 1 of the priority application and

SEQ ID NO: 1 of the patent were not the same. The sequence mentioned in the patent was shorter, lacking 8 amino acids at the N-terminus compared to the sequence disclosed in the priority document.

The disclosure on page 21, lines 19-22 of the priority document that "Analysis of the cDNA [...] indicated the presence in SEQ ID NO: 1 of a long [open reading frame] (ORF) that began at position 239, and ended with the stop codon TAA at positions 2204-6" was not a direct and unambiguous disclosure of SEQ ID NO: 1 mentioned in the patent because, although this ORF encoded a protein with a 655 amino acid length, the existence of other long ORFs was not excluded.

Furthermore, throughout the priority document the invention was disclosed as pertaining to a Breast Cancer Resistance Protein (BCRP) of 663 amino acids in length, with only one passage referring to an ORF encoding a 655 amino acid long protein, which was not even disclosed as a BCRP variant. Thus, the skilled person would have understood that the priority application disclosed a protein having the sequence shown in figure 2A, which had a length of 663 amino acids. The single disclosure of an ORF at one single position in the priority document, in contradiction to the remaining disclosure of the whole document, could not be regarded as a direct and unambiguous disclosure.

Since the polypeptide of SEQ ID NO: 1 was not entitled to priority, documents D3 to D5 were prior art for this subject-matter.

The subject-matter of claims 1 to 3 lacked novelty with respect to the disclosure of document D3.

The subject-matter of claims 4, 5 and 6 lacked inventive step over document D3 in combination with document D13.

The subject-matter of claims 7 and 8 lacked inventive step over document D3 in combination with document D15.

The subject-matter of claims 10 lacked inventive step over document D3 in combination with document D14.

The subject-matter of claims 11, 13 and 14 lacked inventive step over document D3 alone.

Finally, the subject-matter of claims 12, 15 and 16 lacked inventive step over document D5 in combination with document D3.

Article 83 EPC - Disclosure of the invention

Claim 12 related to a "Method of diagnosing a patient's resistance to chemotherapy manifested by overexpression of BCRP". However, in paragraph [0031] of the patent it was disclosed that the degree of resistance did not correlate with the level of expression. On this basis it must be concluded that there was no disclosure in the patent which would allow the person skilled in the art carry out the method as claimed because there was no guidance about which level of drug resistance was caused by the overexpression of the breast cancer resistance gene (BCRP).

XIV. The respondent's arguments relevant to the decision can be summarised as follows:

Article 12(4) RPBA - Admissibility

Document D19

Document D19 should not be admitted into the appeal proceedings. According to decision T 1002/92, the admittance of new documents at the appeal stage should be allowed only very exceptionally if that material is prima facie highly relevant. Document D19 document was not prima facie relevant and moreover represented an attempt to revisit the issue of inventive step of the subject-matter of claim 9 after the appellant had failed to achieve revocation of the claim based on the document that had been used before the opposition division.

Articles 54 and 56 EPC - Novelty and Inventive step

Document D1

The disclosure of document D1 did not anticipate the subject-matter of claim 2. By virtue of its dependency on claim 1, all subject-matter of claim 2 included the full sequence of SEQ ID NO. 1. Thus claim 2 did not encompass fragments of SEQ ID NO: 1. Furthermore, EST157481 had only 98% identity over the region of overlap to the sequence represented by SEQ ID NO: 1. A 180 amino acid long fragment having 100% identity to parts of SEQ ID NO: 1 was not disclosed as a separate entity in document D1.

Documents D3 to D5

Article 87 EPC - Priority right

The priority document on page 21, lines 17-22 disclosed an open reading frame (ORF) beginning at position 239 and ending at the codon 2204-6. This ORF encoded 655 amino acids which were shown in translation from the nucleic acid in Figure 2A. There was therefore a literal, direct and unambiguous disclosure of the 655 amino acid protein designated SEQ ID NO: 1 in the patent.

Claims 1 to 8 and 12 to 16 were thus all entitled to priority. Since documents D3 to D5 post-dated the validly claimed priority date, the objections of lack of novelty and inventive step set in relation to these claims on the basis of these documents could not succeed.

Article 83 EPC - Disclosure of the invention

In the objections under Article 83 EPC, raised against the subject-matter of claim 12, the appellant had misinterpreted paragraph [0031] of the patent which allegedly disclosed that the degree of resistance to chemotherapy did not correlate to the level of expression of BCRP. In fact, the passage indicated that for two groups of cells, both of which exhibited drug resistance (albeit different levels of drug resistance), BCRP mRNA levels were the same. Thus, overexpression of BCRP was correlated with drug resistance in both cell lines.

Moreover, the method of claim 12 did not require that the level of overexpression be measured but merely required that overexpression of the polypeptide was indicative of the cause of resistance to chemotherapy. This was confirmed in paragraph [0031] of the patent which disclosed that the level of resistance varied between the tested cell lines but in both cases was linked to overexpression of BCRP.

XV. The requests of the parties were as follows:

The appellant requested that the decision of the opposition division be set aside and that the patent be revoked.

The respondent requested that the appeal be dismissed, i.e. that the patent be maintained in the form allowed by the opposition division.

Article 12(4) RPBA - Admissibility

Document D19

1. In the statement of grounds of appeal, the appellant introduced a line of argument of lack of inventive step of the subject-matter of claim 9 based on document D19 which had not been raised in the proceedings before the opposition division (see Section XIII.XIII. ). The appellant indicated that the document had been cited on page 3 of the patent in the section "Background of the Invention" and therefore the document was known to the respondent. Its disclosure allowed the skilled person to "unequivocally arrive at the solution provided in claim 9". Thus, the appellant regarded the document as highly relevant.

2. Article 12(1) RPBA provides, inter alia, that the appeal proceedings shall be based on the statement of grounds of appeal. By virtue of Article 12(4) RPBA the board has the power to hold inadmissible facts, evidence or requests which were filed with the statement of grounds of appeal if they "could have been presented [...] in the first instance proceedings".

3. The appellant had been informed by the board's communication that the admission of document D19 was an issue, but has provided no further comments on the matter in writing and also withdrew the request for oral proceedings.

4. The board is of the opinion that document D19 and the line of argument based on it could and should have been presented during opposition proceedings for the same reasons given by the appellant in favour of its admission, namely that, at the time of the opposition proceedings, the appellant was aware of the existence of the document and considered it as highly relevant.

5. In view of this and also taking into consideration that the purpose of appeal proceedings is mainly to review the decision of the department of first instance (see decisions R 10/09, reasons 3.2, R 11/11, reasons 9 and R 13/11, reasons 16), the board, has decided not to admit document D19 into the proceedings.

Articles 54 and 56 EPC- Novelty and Inventive Step

Document D1

6. The appellant argued that EST 157481 disclosed in document D1 was an ABC transporter protein which was 100% identical to a polypeptide having SEQ ID NO: 1 over a stretch of 180 amino acids. It therefore should be considered to be a fragment of SEQ ID NO: 1. The subject-matter of claim 2 included fragments of polypeptides having SEQ ID NO: 1 because the term "about", used in the claim, meant that the claim was "improperly dependent" on claim 1.

7. However, in the board's view, the skilled person reading claim 2 would consider it to relate to subject-matter including all the features of the subject-matter of claim 1 and therefore to be dependent on that claim (Rule 43(4) EPC). Since the subject-matter of claim 1 is a "Polypeptide having the sequence of SEQ ID NO: 1", the subject-matter of claim 2 is considered to be any polypeptide containing the entire amino acid sequence SEQ ID NO: 1. Thus, the skilled person would not consider that fragments of the polypeptide of claim 1 were subject-matter of claim 2.

8. In view of the above, the appellant's argument cannot succeed. The board is satisfied that the subject-matter of claim 2 is novel with respect to the disclosure of document D1.

Documents D3 to D5

Article 87 EPC - Priority right

9. There is a dispute between the parties about whether the subject-matter of claim 1 can validly claim a right of priority from the earlier application US 60/073 763 filed on 5 February 1998.

10. According to Article 87 EPC a European patent application may validly claim the right of priority from a previous first application if both relate to "the same invention". The concept of "the same invention" expressed in Article 87 EPC has been interpreted by the Enlarged Board of Appeal in decision G 2/98 (OJ EPO 2001, 413, point 9 of the reasons) as meaning subject-matter which the person skilled in the art can derive directly and unambiguously, using common general knowledge, from the previous application as a whole.

11. In the present case, the issue is thus whether the 655 amino acid polypeptide having the sequence of SEQ ID NO: 1, that is the subject-matter of claim 1, can be directly and unambiguously derived from application

US 60/073 763.

12. The board notes that the application US 60/073 763 does not contain a discrete sequence identical to

SEQ ID NO: 1 of the patent. However in Example 6 there is a disclosure of a "cDNA insert [...] 2418 bp in length as in Figure 2C or SEQ ID NO: 2 [with] a long ORF that began at position 239 and ended with the stop codon TAA at position 2204-06." (see page 21, lines 17 to 22). Translation of this ORF yields a protein of 655 amino acids which is identical to SEQ ID NO: 1 as mentioned in the patent - it being part of the basic technical knowledge of the skilled person that translation of a nucleic acid sequence into the corresponding amino acid leads to a defined amino acid sequence. Furthermore, the translated amino acid sequence of this region is included in the longer sequence shown in Figure 2A of the priority application. Thus, the board is satisfied that, given the information about the positions of the start and stop codons of the ORF concerned, the skilled person can derive the polypeptide having SEQ ID NO: 1 as claimed, directly and unambiguously, using common general knowledge, from application US 60/073 763 as a whole.

13. It follows from this that the subject-matter of claim 1 and of the dependent claims 2 to 8 and 10 to 16 validly claims the priority date from application US 60/073763, this date being 5 February 1998.

14. Since documents D3 to D5 are all published after that date, all objections of lack of novelty and lack of inventive step made on the basis of these documents must fail.

15. Hence, the board is satisfied that the requirements of Articles 54 and 56 EPC are fulfilled.

Disclosure of the invention - Article 83 EPC

16. The appellant considered that the patent did not disclose the method of claim 12 for determining the cause of a patient's resistance to cancer chemotherapy drugs by assaying in vitro for expression of the polypeptide of claim 1, in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art. In particular, the appellant considered that paragraph [0031] of the patent disclosed that the degree of resistance to the drug did not correlate with the level of expression of the Breast Cancer Resistance Protein (BCRP). In the absence of such a correlation, the method could not be carried out as claimed.

17. However, the board, in agreement with the opposition division and with the respondent, considers that the disclosure at paragraph [0031] of the patent demonstrates that, although the two groups of cells examined exhibit different levels of drug resistance, both are in fact drug resistant. Thus, the patent discloses to the skilled person that expression of BCRP in a cell is correlated to resistance to cancer chemotherapy.

18. The board is therefore satisfied that the patent meets the requirements of Article 83 EPC with respect to the subject-matter of claim 12.

Order

For these reasons it is decided that:

1. The appeal is dismissed.

Footer - Service & support
  • Service & support
    • FAQ
    • Contact us
    • Subscription centre
    • Official holidays
    • Publications
    • Procedural communications
    • Ordering
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
SoMe facebook 0
European Patent Office
EPO Jobs
SoMe instagram
EuropeanPatentOffice
SoMe linkedIn
European Patent Office
EPO Jobs
EPO Procurement
SoMe twitter
EPOorg
EPOjobs
SoMe youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility